The estimated Net Worth of Daniel N Jr Swisher is at least $4.72 Milion dollars as of 1 August 2024. Mr. Swisher owns over 150 units of Jazz Pharmaceuticals plc stock worth over $15,770 and over the last 19 years he sold JAZZ stock worth over $0. In addition, he makes $4,707,410 as President a Chief Operating Officer at Jazz Pharmaceuticals plc.
Daniel has made over 42 trades of the Jazz Pharmaceuticals plc stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 150 units of JAZZ stock worth $879 on 1 August 2024.
The largest trade he's ever made was buying 476,487 units of Jazz Pharmaceuticals plc stock on 30 June 2010 worth over $133,416. On average, Daniel trades about 7,856 units every 64 days since 2005. As of 1 August 2024 he still owns at least 150 units of Jazz Pharmaceuticals plc stock.
You can see the complete history of Mr. Swisher stock trades at the bottom of the page.
Daniel (Dan) N. Swisher Jr. serves as President, Chief Operating Officer of the Company. He was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001, Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation from 1992 to 2001. He currently serves as Chairman of the board of directors of Cerus Corporation, a biomedical products company focused on the field of blood transfusion safety, and as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating therapeutics to address metabolic and other serious medical conditions.
As the President a Chief Operating Officer of Jazz Pharmaceuticals plc, the total compensation of Daniel Swisher at Jazz Pharmaceuticals plc is $4,707,410. There are 1 executives at Jazz Pharmaceuticals plc getting paid more, with Bruce Cozadd having the highest compensation of $14,713,600.
Daniel Swisher is 57, he's been the President a Chief Operating Officer of Jazz Pharmaceuticals plc since 2018. There are 11 older and 16 younger executives at Jazz Pharmaceuticals plc. The oldest executive at Jazz Pharmaceuticals plc is Catherine Sohn, 67, who is the Independent Director.
Daniel's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065.
Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over $1,513,676,247 worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth $25,188,964 . The most active insiders traders include Michael W Michelson, Patrick G Enright a Jp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of $5,162,934. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth $152,703.
jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni
Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include: